- Rocket Doctor AI posts C$0.5M revenue in Q2 2025, its first topline figures
- Gross margin hits 89 per cent following the Rocket Doctor acquisition
- U.S. growth supported by a Medi-Cal deal and a university rollout
- Rocket Doctor AI stock (CSE:AIDR) last traded at $0.66
Rocket Doctor AI Inc. (CSE:AIDR), formerly Treatment.com AI Inc., has reported its first-ever revenues of C$0.5 million in the second quarter of 2025, marking a turning point for the Canadian healthtech firm.
The gains stem from its April acquisition of Rocket Doctor Inc., a digital health platform that has expanded the company’s footprint into the United States and into medical education.
This content has been prepared as part of a partnership with Rocket Doctor AI and is intended for informational purposes only.
The Q2 topline compares to no revenue in both Q1 2025 and Q2 2024. Gross margin climbed to 89 per cent, reflecting the leverage of the acquired platform.
“We are very excited to announce our first significant revenue producing quarter for the company,” said Dr. Essam Hamza, CEO of Rocket Doctor AI Inc.. He added, “This was an important quarter for us that saw the completion of the Rocket Doctor Inc. acquisition, advancement of our GLM technology, and the announcement of new contracts contributing to our US expansion.”
Despite the new revenue, Rocket Doctor AI posted a net comprehensive loss of C$2.7 million, or C$0.04 per share, a slight widening from the C$2.1 million loss in Q1. Adjusted EBITDA came in at a negative C$1.7 million, compared to a loss of C$1.2 million in the previous quarter.
The company’s new digital health platform now supports more than 300 clinicians and has facilitated over 600,000 patient visits to date.
Expansion initiatives included a virtual care partnership with the Central California Alliance for Health, a Medi-Cal plan serving around 450,000 members, as well as the launch of its Medical Education Suite (MES) for 240 medical students at the University of Minnesota.
Both moves are aimed at validating the company’s AI-driven clinical and educational tools in large-scale, real-world settings.
Q2 2025 marks a clear inflection point for the company: revenue generation, strong margins, and building U.S. presence.
As it navigates near-term liquidity challenges and ramps up its GLM-powered tools, the focus will be on converting new contracts into sustainable growth—particularly in virtual care and medical education.
Rocket Doctor AI stock (CSE:AIDR) closed Friday trading 6.45 per cent higher at $0.66.
Join the discussion: Find out what the Bullboards are saying about Rocket Doctor AI and check out Stockhouse’s stock forums and message boards.
Stockhouse does not provide investment advice or recommendations. All investment decisions should be made based on your own research and consultation with a registered investment professional. The issuer is solely responsible for the accuracy of the information contained herein. For full disclaimer information, please click here.
